oxybutynin and Musculoskeletal Pain

oxybutynin has been researched along with Musculoskeletal Pain in 3 studies

oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.

Musculoskeletal Pain: Discomfort stemming from muscles, LIGAMENTS, tendons, and bones.

Research

Studies (3)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Efficacy According to BS-11 Pain Score Reduction

"The primary efficacy outcome analysis is the pre- and post-intervention change in BS-11 pain score. The reduction in scores were calculated by subtracting the post-intervention score from the baseline score.~BS-11 is known as Box scale-11; it is an 11-point scale measuring pain intensity. It ranges from 0 to 10, whereby 0 represents no pain and 10 represents the worst imaginable pain. Subjects selected a number based on the pain intensity they were feeling at that time." (NCT01961271)
Timeframe: Maximum 17 weeks starting from enrolment

Secondary Efficacy Outcome -- Incidence of Early Treatment Discontinuation Due to Lack of Efficacy.

(NCT01961271)
Timeframe: From time of enrolment to Visit 6 (ie. up to119 days from enrolment)

Secondary Efficacy Outcome as Measured by Number of Subjects Requiring at Least 1 Breakthrough (Rescue) Pain Medication

Daily use of breakthrough pain medication from visits 1-6, assessed from patient diaries. (NCT01961271)
Timeframe: Approximately 17 weeks starting from enrolment

Treatment-emergent Adverse Events (TEAE's) as Measured by Number of Subjects With at Least 1 TEAE

Side effects of the transdermal patch treatment will be analysed. (NCT01961271)
Timeframe: From time of enrolment up to 7 days after completion / discontinuation visit (up to 140 days)

Secondary Efficacy Outcome Determined by Change in Percentage of Subjects Who Met Criteria on EQ5D-3L Quality of Life Questionnaire From Pre- to Post-intervention

"Pre-intervention: Visit 1 Post-intervention: Visit 6~There are 5 dimensions in the EQ5D-3L questionnaire answered by the subjects, classified into 5 categories here:~Mobility -- change in % of subjects who have no problem in walking around Self-care -- change in % of subjects who have no problem in self-care Usual activities -- change in % of subjects who have no problem with performing their usual activities Pain/ discomfort -- change in % of subjects who do not experience pain or discomfort Anxiety/ depression -- change in % of subjects who do not feel anxious or depressed" (NCT01961271)
Timeframe: approximately 17 weeks starting from enrolment

Secondary Efficacy Outcome on Physicians' and Patients' Treatment Satisfaction Assessed Using Physician's Global Impression of Change Scale and Patient's Global Impression of Change Scale Respectively

"The overall assessment of the change in pain intensity from baseline is measured at Visit 6.~Physician's Global Impression of Change scale: Investigator's opinion on a scale of 1 to 7 where 1 is very much improved and 7 is very much worse Patient's Global Impression of Change scale: Subject's opinion on a scale of 1 to 7 where 1 is very much improved and 7 is very much worse" (NCT01961271)
Timeframe: At visit 6 (anywhere between Day 91 to 119 after enrolment depending on how long titration took)

Trials

2 trials available for oxybutynin and Musculoskeletal Pain

Other Studies

1 other study available for oxybutynin and Musculoskeletal Pain